Related Experiment Video
Updated: Sep 12, 2025

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
Expediting Drug Development in Japan: A PMDA Perspective
Yoichi Kohno1, Akihiro Ishiguro2, Takashi Yasukawa1
1Center for Product Evaluation, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Abstract:
Review time for a new drug in Japan has shortened dramatically since the establishment of the Pharmaceuticals and Medical Devices Agency (PMDA). Nonetheless, Japan faces a new challenge so-called "Drug Loss", which means that new drugs approved overseas have not yet been developed in Japan or that development is delayed. In this manuscript, we describe how PMDA facilitates Japan's drug development to continuously provide innovative drugs to patients.
More Related Videos
05:16Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
Published on: May 7, 2020
09:34Improved Polymerase Chain Reaction-restriction Fragment Length Polymorphism Genotyping of Toxic Pufferfish by Liquid Chromatography/Mass Spectrometry
Published on: September 20, 2016
Related Concept Videos
Drug Regulation
Preclinical Development: Overview
Clinical Trials: Overview
Drug Discovery: Overview
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...